Promising AI-Designed Vaccine Passes First Human Trial
A groundbreaking vaccine developed using artificial intelligence has successfully completed its first human clinical trial. This innovative “universal vaccine” aims to shield people from various coronaviruses and prepare for possible future outbreaks.
Researchers from the Universities of Cambridge and Southampton created this vaccine to target multiple Sarbeco coronaviruses, a group that includes SARS-CoV-2, the virus responsible for the COVID-19 pandemic.
According to Professor Saul Faust, the trial’s lead investigator from the University of Southampton, traditional vaccines face a constant challenge. He described the situation as “like a dog chasing its tail,” explaining that as viruses like influenza and coronaviruses mutate, vaccines quickly become outdated. By the time new vaccines are available, they may not effectively match the current strains.
The scientists used artificial intelligence to analyze all the genetic sequences of Sarbeco coronaviruses. They designed a “super-antigen,” which includes features that could protect against both known and yet-to-emerge viruses.
In a trial involving 39 healthy volunteers, the vaccine was found to be safe and effective in triggering an immune response. Notably, this trial marks the first time an entirely computer-designed active component has been tested in humans.
The vaccine is administered using a micro-fluid jet, which delivers the liquid through the skin without the need for needles. Researchers believe this method could simplify the process of immunizing large groups of people quickly.
“This new class of universal vaccines is designed to be future-proof,” said Professor Faust. He emphasized that these vaccines can potentially protect against multiple variants at once and could be effective against related viruses that have not yet crossed into human populations. If successful, this approach could save countless lives by preventing outbreaks before they begin.
While many celebrate these advancements, experts have also raised concerns about using AI in medical applications. Some warn that AI may underrepresent certain populations in its data, leading to biased outcomes, while others point out the potential for AI to generate incorrect information, complicating accountability in medical situations.
Moreover, there are worries regarding patient privacy and the importance of human judgment, which considers a patient’s comprehensive health history rather than relying solely on data.
The researchers acknowledged the need for larger trials involving more diverse populations and published their findings in the Journal of Infection.
